Wall Street Analysts Are Bullish on Top Healthcare Picks

view original post

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Forte Biosciences (FBRXResearch Report) and Alcon (ALCResearch Report) with bullish sentiments.

Invest with Confidence:

Forte Biosciences (FBRX)

Forte Biosciences received a Buy rating from TD Cowen analyst Yaron Werber today. The company’s shares closed last Friday at $15.60.

According to TipRanks.com, Werber is a 4-star analyst with an average return of 8.0% and a 48.4% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Springworks Therapeutics, and Ionis Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Forte Biosciences.

See Insiders’ Hot Stocks on TipRanks >>

Alcon (ALC)

In a report released today, Graham Doyle from UBS maintained a Buy rating on Alcon, with a price target of CHF95.00. The company’s shares closed last Friday at $84.37.

Doyle has an average return of 2.2% when recommending Alcon.

According to TipRanks.com, Doyle is ranked #8500 out of 9284 analysts.

Currently, the analyst consensus on Alcon is a Strong Buy with an average price target of $100.03, which is a 18.3% upside from current levels. In a report issued on January 10, Redburn Atlantic also upgraded the stock to Buy with a CHF93.00 price target.

Read More on FBRX: